While carglumic acid, approved for treatment of N-acetylglutamate synthase deficiency, can be used to treat a subset of CPS1-deficient patients, this is not a broadly applicable therapeutic option as it depends on a CPS1 mutation with residual enzyme activity.10 This evidence concerns the gene CPS1 and hyperammonemia due to N-acetylglutamate synthase deficiency.